{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-044891","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.773518+00:00","generated_at":"2026-06-07T12:50:48.291291+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"BriaCell's BriaPro subsidiary posts Q1 loss of $128K; holds $211K in intangible assets","bullets":["BriaPro completed spin-out from BriaCell on Aug 31, 2023, receiving Bria-TILsRx and PKCδ inhibitor assets.","Net loss of $128K for three months ended Oct 31, 2023; no revenue; operating loss $132K.","Intangible assets (patents) of $211K net; cash and equivalents of $1; accumulated deficit $148K.","Going concern uncertainty noted; BriaPro needs additional financing to continue operations.","BriaCell owns 2/3 of BriaPro; provides transition services for $20K/month."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-044891","json":"https://secwatch.observer/filing/0001493152-23-044891.json","markdown":"https://secwatch.observer/filing/0001493152-23-044891.md","text":"https://secwatch.observer/filing/0001493152-23-044891.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223044891/0001493152-23-044891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223044891/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:50:48.291291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}